Navigation Links
Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
Date:10/23/2007

g, and an initial response rate of approximately 70 percent to this type of chemotherapy regimen can be anticipated. In spite of initial response rates, recurrence rates among ovarian cancer patients are high, and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc. Other trademarks are the property of their respective owners.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy and commercial potential of SNS-595, planned additional clinical testing and development efforts and the anticipated timing of the completion of enrollment in the ongoing Phase 2 clinical trial and the announcement of clinical results. Words such as "look forward," "suggests," "may," "plans," "expects," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   MacPractice,s MacPractice MD ... Complete EHR certification, which designates that the software is ... 1 and Stage 2 Meaningful Use measures required to ... Act (ARRA).  MacPractice MD MU version 5.0 was certified ... an Office of the National Coordinator-Authorized Certification Body (ONC-ACB) ...
(Date:9/18/2014)... --This BCC Research report discusses the medical device technologies in ... size, and opportunities for different devices and regions. It includes ... in the report focuses on technological trends in recent years ... and Japan . ... medical device technologies market. - Analyze market structure, including segments ...
(Date:9/18/2014)... , Sept. 18, 2014  KIYATEC announced ... million Small Business Innovation Research (SBIR) Phase II ... of the 27 institutes and centers that comprise ... course of the two year award, KIYATEC will ... two issues at the forefront of cancer therapy ...
Breaking Medicine Technology:MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3
... March 2007 - Cancer drug,developer Antisoma plc (LSE: ... from its second, confirmatory phase II,trial of AS1404 ... trial tested an 1800 mg/m2 dose of AS1404 ... response rate of 50%. A further 43% of,patients ...
... BioSciences,Inc., a specialty dermatology company, today announced the,publication of ... the journal,Cell by its co-founder and board member, David ... an important protein,p53, in the pigmentation of skin. Fisher's ... tumor suppressor in other cancers in,the body, p53 also ...
Cached Medicine Technology:Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 2Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 3Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein 2
(Date:9/18/2014)... September 18, 2014 Alexandria, VA — ... today that 10 more communities have joined the growing ... health department accreditation. The decisions bring the number of ... 54. PHAB is the non-profit organization that administers the ... and protect the health of the public by advancing ...
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Rising temperatures in the ... spread to shallow waters that are becoming warmer, an ... reefs, ecologists report. A study of 40 species ... northward movement by the invasive and poisonous lionfish, according ... (NOAA) and the University of North Carolina-Wilmington, who published ...
(Date:9/18/2014)... "Medical staff need better ways to ... the patient's privacy," said one of two inventors from ... order to supply caregivers with the equipment they need ... prototype for The Helper to make it easier to ... patient onto his or her side. It also securely ...
(Date:9/18/2014)... One of the most capable and sophisticated ... ShandsCair Flight Program’s new EC155 B1, will be ... the Air Medical Transport Conference (AMTC), Sept. 22-24, in ... service ShandsCair EC155 and the Vanderbilt University LifeFlight ... highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... patients seeking care at larger urban hospitals are likely to ... at smaller or more rural facilities, new research suggests. ... emergency care varies dramatically across hospitals in the United States," ... Renee Hsia, an associate professor at the University of California, ...
Breaking Medicine News(10 mins):Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3
... ... a clinical trial that is testing whether specialized contact lenses can slow or halt ... and Robert Davis, working with EyeVis Eye and Vision Research Institute, recently reported on ... , ...
... Family Research Council President Tony Perkins responded to ... Obama,s executive order for federal funding of human embryonic ... the NIH guidelines remove life-protecting limits on federal funding ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) ...
... ... a national leader in accounts receivable management, and collection services to the healthcare industry has ... in Vero Beach, Florida. , ... Vero Beach, FL (PRWEB) July 7, 2009 -- National healthcare receivables industry leader, Medical ...
... a Woman,s Right to Choose , , ARLINGTON ... breast reconstruction procedures performed in 2008, nearly 70 percent ... not informed of the reconstructive options available to them, ... by the American Society of Plastic Surgeons (ASPS) shows ...
... July 7 The Anthropedia Foundation, a non-profit organization ... Know Yourself , an innovative DVD series designed ... and healthier lives. The series is a step-by-step guide ... part focuses on straightforward concepts and simple exercises that ...
... sellers appears to reduce the trafficking of guns to ... the Johns Hopkins Bloomberg School of Public Health. Preventing ... 85 percent of guns recovered by police were recovered ... of the guns according to prior research from the ...
Cached Medicine News:Health News:Can a Contact Lens Cure Nearsightedness? Five-Year Clinical Study Testing Corneal Reshaping Therapy as Possible Method to Arrest Myopia 2Health News:Can a Contact Lens Cure Nearsightedness? Five-Year Clinical Study Testing Corneal Reshaping Therapy as Possible Method to Arrest Myopia 3Health News:NIH Stem Cell Guidelines Ethically Irresponsible, Scientifically Unworthy, Useless to Patients, Says Family Research Council 2Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 2Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 3Health News:Are Breast Cancer Patients Being Kept In The Dark? 2Health News:Knowing Yourself Can Improve Your Health and Happiness 2Health News:Knowing Yourself Can Improve Your Health and Happiness 3Health News:Regulation and oversight of gun sales reduces trafficking to criminals 2Health News:Regulation and oversight of gun sales reduces trafficking to criminals 3
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: